Tirzepatide for heart health in young cancer survivors
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests whether tirzepatide, a weekly injection that helps with weight loss and blood sugar control, can protect the heart in young adults who survived sarcoma and are now overweight or obese. The goal is to see if this treatment can reduce the risk of heart problems caused by previous chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 39 years old.
- You had sarcoma (a type of cancer in bone or soft tissue) and received a chemotherapy drug called doxorubicin (also known as 'Adriamycin') at a cumulative dose of at least 300 mg/m².
- You finished chemotherapy at least 3 months ago and are currently in remission, with no planned cancer treatments for the next year.
- You are overweight (BMI 25-29.9 with at least one cardiovascular risk factor like high blood pressure, high cholesterol, or family history) or obese (BMI 30 or higher).
- Your heart function is at least 50% (measured by an echocardiogram) and you do not have symptoms of heart failure (like shortness of breath or swelling).
- You are willing to use effective contraception during the study (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests retifanlimab (an immunotherapy that helps your immune system recognize cancer) combined with gemcitabine and docetaxel chemotherapy. It’s for people with advanced soft tissue sarcoma that can’t be safely removed with surgery, aiming to shrink tumors and improve outcomes.
This trial tests whether combining seed radiation (iodine-125 placed in/near the tumor) with fluzoparib can better control advanced, hard-to-remove soft tissue sarcoma. It may help shrink tumors and slow progression, but you must meet several cancer, health, and safety requirements.
This trial tests a combination of immunotherapy (atezolizumab), chemotherapy (doxorubicin), and radiation before and after surgery for people with high-risk soft tissue sarcoma in the arm, leg, or trunk. The goal is to see if this approach can improve outcomes.
This trial tests if combining four drugs (pazopanib, trabectedin, ipilimumab, and nivolumab) can help treat soft tissue sarcomas that have come back. It is for children and young adults up to age 30.
This trial tests whether a medicine injected directly into a tumor can shrink or control advanced soft tissue sarcoma. It mainly looks for people whose tumors can be safely injected with a hand exam or ultrasound.
This trial tests trabectedin plus ipilimumab and nivolumab in people with advanced soft-tissue sarcoma that has already been treated. It aims to see how well this combination works and how safely it can be given.
Hear when a new Sarcoma,Soft Tissue trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.